Received Feb 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | — | — |
mild stroke; memory declined/decreased memory functioning/memory loss; This is a solicited report received from an Other HCP and a Consumer or other non HCP, Program ID. A 76-year-old male patient received BNT162b2 (BNT162B2 NOS), in 2022 as dose 2, single (Batch/Lot number: unknown) at the age of 76 for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, unknown manufacturer), for Covid-19 immunization. The following information was reported: MEMORY IMPAIRMENT (non-serious) with onset 2022, outcome "unknown", described as "memory declined/decreased memory functioning/memory loss"; CEREBROVASCULAR ACCIDENT (medically significant), outcome "unknown", described as "mild stroke". The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received. Clinical course: Patient reported after the start of therapy, patient has "more" energy (new onset) on going and able to function multiple task. MD aware. Patient reports memory loss is getting "worse & worse" forgetful, "not" from vyndamax; patient referenced memory declined/decreased memory functioning due to getting older (aging), "covid" (prior to start of therapy ) & from second "covid shot" 2022 (unknown specific name of covid shot) as the following day patient noted memory loss could be a "mild stroke" (onset prior to start of therapy) MD aware. Vyndamax 61 mg capsule (take 1 capsule oral once a day. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.; Sender's Comments: Based on the temporal association and reporter's attribution, the events cerebrovascular accident and memory impairment can possibly have causal relation with the suspect product, BNT162b2 (BNT162B2 NOS). The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.